


SCHEDULE 7

TO THE PROTOCOL FOR THE AVAT NO FAULT COMPENSATION SCHEME

ILLUSTRATION OF REPORTING PERIOD

UNDER THE AVAT NO FAULT COMPENSATION SCHEME¹



¹ NOTE: A Vaccine must be administered to the Patient before the end of the first 24 months period. An Application in respect of a Vaccine administered **after** this first 24 months period will **not** be receivable for compensation under the Program.

For each Patient, the Reporting Period depends on the date the Vaccine was administered to the Patient. To calculate the Reporting Period that applies to the Patient, the Patient (or the person who is a duly authorized to represent the Patient) needs to:

- Determine (through Schedule 1 to the Protocol) what is the date of the Scope of Coverage End Point that applies to the Vaccine that was administered to Patient; and
- Calculate the number of months and days from the vaccination date (i.e. date that the Vaccine was administered to the Patient) until the date of the Vaccine's Scope of Coverage End Point, and add another 36 months. This establishes the Reporting Period that applies to the Patient.

ILLUSTRATION OF REPORTING PERIOD FOR:

J&J (JANSSEN)
SARS-CoV-2 Vaccine, Ad26.COVS recombinant

UNDER THE AVAT NO FAULT COMPENSATION SCHEME²

Start of Reporting
Period:

Date Vaccine is
first distributed
under the AVAT
Framework
(See Schedule 1 to
the Protocol)

Vaccine's "Scope of
Coverage Endpoint"

(See Schedule 1 to the
Protocol)


End of Reporting
Period

(See Schedule 1 to the
Protocol)

5 August 2021

4 August 2023

4 August 2026



² NOTE: A Vaccine must be administered to the Patient before the end of the first 24 months period. An Application in respect of a Vaccine administered **after** this first 24 months period will **not** be receivable for compensation under the Program.